Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Development services for gene and cell therapies is planned to begin first in 2025
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Dr. Karikó is the third Solvay Prize winner to become a Nobel Prize laureate
Good momentum in commercial CDMO business
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Supply readiness follows months of manufacturing to ensure timely and ample supply
Subscribe To Our Newsletter & Stay Updated
